SCHEMBL35212060

SCHEMBL35212060

COc1cc2c3n(nc2c(Cl)c1Cl)CCN(C(=O)CO)[C@H]3C

nearest known ligand 0.33

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 7/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ EGFR P00533 1/20 0.32
▸ EHMT2 Q96KQ7 1/20 0.32
▸ ALK Q9UM73 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ SHMT2 P34897 1/20 0.31
▸ MAPT P10636 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ MTNR1A P48039 1/20 0.30
▸ MTNR1B P49286 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL35212408 1.00 CCR1 (0.33) CCR1KMT2AMEN1CYP3A4CYP2C19
SCHEMBL35212409 1.00 CCR1 (0.33) CCR1KMT2AMEN1CYP3A4CYP2C19
SCHEMBL35212553 1.00 CCR1 (0.33) CCR1KMT2AMEN1CYP3A4CYP2C19
SCHEMBL35211140 0.93 ALDH1A1 (0.36) CCR1KMT2AMEN1CYP3A4CYP2C19
SCHEMBL35210835 0.93 ALDH1A1 (0.36) CCR1KMT2AMEN1CYP3A4CYP2C19
SCHEMBL35211486 0.92 KMT2A (0.32) CCR1KMT2AMEN1CYP3A4CYP2C19
SCHEMBL35211434 0.92 KMT2A (0.32) CCR1KMT2AMEN1CYP3A4CYP2C19
SCHEMBL35211047 0.92 KMT2A (0.32) CCR1KMT2AMEN1CYP3A4CYP2C19
SCHEMBL35211308 0.88 CCNT1 (0.34) CCR1KMT2AMTNR1AMTNR1B
SCHEMBL35211452 0.88 CCNT1 (0.34) CCR1KMT2AMTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125383-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2026-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125383-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF CGAS, PRKG1, GMPS CCR1 930/4885KMT2A 4761/4885MEN1 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback